ELITE PHARMACEUTICALS INC /NV/ (ELTP) Company Report

Analyst Earnings Quarterly Reports

Earnings summaries and quarterly performance for ELITE PHARMACEUTICALS INC /NV/.

Research analysts covering ELITE PHARMACEUTICALS INC /NV/.

Recent press releases and 8-K filings for ELTP.

Elite Pharmaceuticals Reports Strong Q2 FY2026 Results Driven by New Product Launches

ELTP

Earnings

Product Launch

M&A

Elite Pharmaceuticals reported strong financial results for Q2 FY2026, with total revenues reaching $36.3 million, a 92% increase compared to the prior year quarter, and $76.5 million for the six months ended September 2025, a 103% increase.
The significant revenue growth was primarily driven by the launch of lisdexamfetamine (generic Vyvanse) in the March 2025 quarter, which now holds an 8% market share.
The company's balance sheet continues to strengthen, with working capital at $75 million as of September 30, 2025, a 63% increase from March 2025, and a trend of decreasing debt.
Elite Pharmaceuticals is actively pursuing Merger and Acquisition (M&A) opportunities as its primary focus for future growth, with several companies expressing interest.
The development pipeline includes Oxycodone ER under FDA review and an undisclosed anticoagulant with an ANDA submission expected in Q1 2026.

Nov 17, 2025, 4:30 PM

Elite Pharmaceuticals Reports Strong Q2 2026 Financial Results and M&A Focus

ELTP

Earnings

Revenue Acceleration/Inflection

M&A

Elite Pharmaceuticals reported Q2 2026 total revenues of $36.3 million, a 92% increase year-over-year, and $76.5 million for the six months ended September 2025, representing a 103% increase.
Profitability saw significant growth, with Q2 2026 gross profit up 72% to $14.1 million and operating profits for the six months ended September 2025 increasing 307% to $29.9 million.
The company's balance sheet strengthened, with working capital rising 63% to $75 million as of September 30, 2025, and operating cash flow for the six months ended September 2025 increasing 333% to $19.9 million.
Key products like Lisdexamfetamine (generic Vyvanse) hold an 8% market share, and Amphetamine IR (generic Adderall) commands 19% market share. The pipeline includes an undisclosed anticoagulant generic expected to be filed in Q1 2026 and Ropinirole launching in Q1/early Q2 2026.
Mergers and acquisitions (M&A) are the primary strategic focus, with the company expecting to exceed $100 million in revenue for the current fiscal year.

Nov 17, 2025, 4:30 PM

Elite Pharmaceuticals Reports Strong Q2 2026 Financial Results Driven by Product Growth

ELTP

Earnings

Revenue Acceleration/Inflection

M&A

Elite Pharmaceuticals reported total revenues of $36.3 million for the second quarter of fiscal year 2026 (ended September 30, 2025), representing a 92% increase compared to the September 2024 quarter. For the six months ended September 2025, total revenues were $76.5 million, a 103% increase over the same period in the prior year.
This substantial revenue growth is attributed to the well-established Elite label products and the Lisdexamfetamine (generic Vyvanse) product line, which was launched in the March 2025 quarter.
The company's gross profit for Q2 2026 increased by 72% to $14.1 million, and operating profits rose by 136% to $8.2 million compared to the September 2024 quarter ,.
Elite Pharmaceuticals continues to strengthen its balance sheet, with working capital increasing by 63% to $75 million as of September 30, 2025, compared to March 2025, and debt continuing to decrease.
Key pipeline updates include the expected Q1 2026 submission of an ANDA for an undisclosed anticoagulant generic and the planned Q1/early Q2 launch of Ropinirole, with M&A remaining a primary strategic focus , ,.

Nov 17, 2025, 4:30 PM

Elite Pharmaceuticals Reports Strong Q2 FY2026 Financial Results

ELTP

Earnings

Revenue Acceleration/Inflection

Product Launch

Elite Pharmaceuticals, Inc. reported consolidated revenues of $36.3 million for the second quarter of fiscal year 2026, an increase of approximately 92% compared to the comparable period of the prior fiscal year.
The company's income from operations was $8.2 million, representing a 136% increase over the comparable period of the prior fiscal year.
This growth was primarily driven by sales of Elite’s lisdexamfetamine products, launched after the comparable prior period, and overall strong performance in Elite label product lines.
Elite Pharmaceuticals will host a conference call on November 17, 2025, at 11:30 AM EST to discuss these financial results and provide a business update.

Nov 14, 2025, 10:10 PM

Elite Pharmaceuticals Receives FDA Approval for Generic Requip XL

ELTP

Product Launch

New Projects/Investments

Elite Pharmaceuticals, Inc. announced on November 12, 2025, that it received FDA approval for an Abbreviated New Drug Application (ANDA) for a generic version of Requip XL® (Ropinirole Extended-Release Tablets USP).
The approved generic product, which will be marketed under the Elite Laboratories, Inc. label, is available in 2 mg, 4 mg, 6 mg, 8 mg, and 12 mg tablet strengths and is used to treat symptoms of Parkinson's disease.
The branded product and its equivalents had total U.S. sales of $10 million for the twelve months ending September 2025.